Akero Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Akero Therapeutics has a total shareholder equity of $738.3M and total debt of $35.1M, which brings its debt-to-equity ratio to 4.8%. Its total assets and total liabilities are $817.5M and $79.2M respectively.
Key information
4.8%
Debt to equity ratio
US$35.12m
Debt
| Interest coverage ratio | n/a |
| Cash | US$717.25m |
| Equity | US$738.33m |
| Total liabilities | US$79.22m |
| Total assets | US$817.55m |
Recent financial health updates
Recent updates
Akero Therapeutics: Good Candidate For The MASH Basket
Sep 20Akero Therapeutics' EFX Data Warrants Caution
Apr 03Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program
Mar 04Akero Therapeutics announces closing of upsized public offering
Sep 19Akero adds over 100% rallying peers after NASH success
Sep 13We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate
May 04
Financial Position Analysis
Short Term Liabilities: AKRO's short term assets ($746.9M) exceed its short term liabilities ($43.3M).
Long Term Liabilities: AKRO's short term assets ($746.9M) exceed its long term liabilities ($35.9M).
Debt to Equity History and Analysis
Debt Level: AKRO has more cash than its total debt.
Reducing Debt: AKRO's debt to equity ratio has increased from 0% to 4.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKRO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AKRO has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 33.9% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:15 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Akero Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Alexandria Hammond | BofA Global Research |
| Edward Nash | Canaccord Genuity |